An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK.

MLA

Viriato, Daniel, et al. “An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK.” Advances in Therapy, vol. 37, no. 3, Mar. 2020, pp. 1233–47. EBSCOhost, https://doi.org/10.1007/s12325-020-01243-y.

APA

Viriato, D., Bennett, N., Sidhu, R., Hancock, E., Lomax, H., Trueman, D., & MacLaren, R. E. (2020). An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK. Advances in Therapy, 37(3), 1233–1247. https://doi.org/10.1007/s12325-020-01243-y

Chicago

Viriato, Daniel, Natalie Bennett, Raisa Sidhu, Elizabeth Hancock, Hannah Lomax, David Trueman, and Robert E. MacLaren. 2020. “An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK.” Advances in Therapy 37 (3): 1233–47. doi:10.1007/s12325-020-01243-y.